Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Auxly Cannabis Group Inc. stock logo
CBWTF
Auxly Cannabis Group
$0.06
+1.7%
$0.06
$0.02
$0.07
$79.36M0.971.09 million shs176,155 shs
MaxCyte, Inc. stock logo
MXCT
MaxCyte
$2.20
-3.1%
$2.45
$2.10
$5.20
$234.12M1.27613,867 shs912,311 shs
Inotiv, Inc. stock logo
NOTV
Inotiv
$2.22
-5.5%
$2.18
$1.15
$6.48
$76.26M4.08579,763 shs543,420 shs
OmniAb, Inc. stock logo
OABI
OmniAb
$1.78
+4.1%
$1.62
$1.22
$4.96
$217.40M-0.03666,087 shs868,307 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Auxly Cannabis Group Inc. stock logo
CBWTF
Auxly Cannabis Group
0.00%+1.01%-11.86%+15.33%+180.00%
MaxCyte, Inc. stock logo
MXCT
MaxCyte
0.00%+2.33%-1.35%-33.13%-56.00%
Inotiv, Inc. stock logo
NOTV
Inotiv
0.00%-17.47%+9.36%-25.50%+29.07%
OmniAb, Inc. stock logo
OABI
OmniAb
0.00%+18.67%+14.84%-46.22%-59.55%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Auxly Cannabis Group Inc. stock logo
CBWTF
Auxly Cannabis Group
0.609 of 5 stars
0.05.00.00.02.20.00.0
MaxCyte, Inc. stock logo
MXCT
MaxCyte
3.5858 of 5 stars
3.55.00.00.02.02.51.3
Inotiv, Inc. stock logo
NOTV
Inotiv
1.9299 of 5 stars
3.51.00.00.02.50.01.3
OmniAb, Inc. stock logo
OABI
OmniAb
3.1173 of 5 stars
3.51.00.00.03.33.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Auxly Cannabis Group Inc. stock logo
CBWTF
Auxly Cannabis Group
0.00
N/AN/AN/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
3.00
Buy$7.50240.91% Upside
Inotiv, Inc. stock logo
NOTV
Inotiv
3.00
Buy$5.00125.23% Upside
OmniAb, Inc. stock logo
OABI
OmniAb
3.00
Buy$7.00293.26% Upside

Current Analyst Ratings Breakdown

Latest CBWTF, MXCT, OABI, and NOTV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2025
OmniAb, Inc. stock logo
OABI
OmniAb
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
5/8/2025
Inotiv, Inc. stock logo
NOTV
Inotiv
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $5.00
3/27/2025
OmniAb, Inc. stock logo
OABI
OmniAb
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$7.00 ➝ $4.00
3/20/2025
OmniAb, Inc. stock logo
OABI
OmniAb
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $6.00
3/19/2025
OmniAb, Inc. stock logo
OABI
OmniAb
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Auxly Cannabis Group Inc. stock logo
CBWTF
Auxly Cannabis Group
$74.87M1.06N/AN/A$0.04 per share1.51
MaxCyte, Inc. stock logo
MXCT
MaxCyte
$37.68M6.21N/AN/A$2.23 per share0.99
Inotiv, Inc. stock logo
NOTV
Inotiv
$480.40M0.16$0.80 per share2.76$5.04 per share0.44
OmniAb, Inc. stock logo
OABI
OmniAb
$26.74M8.13N/AN/A$2.69 per share0.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Auxly Cannabis Group Inc. stock logo
CBWTF
Auxly Cannabis Group
-$32.97M$0.01N/AN/A-65.48%-80.40%-28.61%N/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-$37.92M-$0.40N/AN/AN/A-78.36%-16.00%-13.93%8/5/2025 (Estimated)
Inotiv, Inc. stock logo
NOTV
Inotiv
-$108.44M-$3.19N/AN/AN/A-25.40%-15.41%-3.58%8/6/2025 (Estimated)
OmniAb, Inc. stock logo
OABI
OmniAb
-$50.62M-$0.58N/AN/AN/A-308.78%-20.97%-18.05%8/6/2025 (Estimated)

Latest CBWTF, MXCT, OABI, and NOTV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Auxly Cannabis Group Inc. stock logo
CBWTF
Auxly Cannabis Group
N/A$0.01N/A$0.01N/AN/A
5/8/2025Q1 2025
OmniAb, Inc. stock logo
OABI
OmniAb
-$0.17-$0.17N/A-$0.17$4.49 million$4.15 million
5/7/2025Q1 2025
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-$0.10-$0.10N/A-$0.10$9.05 million$10.39 million
5/7/2025Q2 2025
Inotiv, Inc. stock logo
NOTV
Inotiv
-$0.24-$0.18+$0.06-$0.44$123.97 million$124.32 million
3/18/2025Q4 2024
OmniAb, Inc. stock logo
OABI
OmniAb
-$0.13-$0.12+$0.01-$0.12$10.13 million$10.80 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Auxly Cannabis Group Inc. stock logo
CBWTF
Auxly Cannabis Group
N/AN/AN/AN/AN/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
N/AN/AN/AN/AN/A
Inotiv, Inc. stock logo
NOTV
Inotiv
N/AN/AN/AN/AN/A
OmniAb, Inc. stock logo
OABI
OmniAb
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Auxly Cannabis Group Inc. stock logo
CBWTF
Auxly Cannabis Group
0.37
0.85
0.48
MaxCyte, Inc. stock logo
MXCT
MaxCyte
N/A
9.81
9.22
Inotiv, Inc. stock logo
NOTV
Inotiv
2.31
1.57
1.28
OmniAb, Inc. stock logo
OABI
OmniAb
N/A
4.62
4.62

Institutional Ownership

CompanyInstitutional Ownership
Auxly Cannabis Group Inc. stock logo
CBWTF
Auxly Cannabis Group
N/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
68.81%
Inotiv, Inc. stock logo
NOTV
Inotiv
18.17%
OmniAb, Inc. stock logo
OABI
OmniAb
72.08%

Insider Ownership

CompanyInsider Ownership
Auxly Cannabis Group Inc. stock logo
CBWTF
Auxly Cannabis Group
4.60%
MaxCyte, Inc. stock logo
MXCT
MaxCyte
3.30%
Inotiv, Inc. stock logo
NOTV
Inotiv
7.80%
OmniAb, Inc. stock logo
OABI
OmniAb
8.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Auxly Cannabis Group Inc. stock logo
CBWTF
Auxly Cannabis Group
3691.32 billion1.25 billionNot Optionable
MaxCyte, Inc. stock logo
MXCT
MaxCyte
80106.42 million102.67 millionOptionable
Inotiv, Inc. stock logo
NOTV
Inotiv
2,10034.35 million31.09 millionOptionable
OmniAb, Inc. stock logo
OABI
OmniAb
7122.14 million129.07 millionOptionable

Recent News About These Companies

Chairman of OmniAb Picks Up 3.0% More Stock
OmniAb Appoints New Directors to Board
Leerink Partners Sticks to Their Buy Rating for OmniAb (OABI)
OmniAb price target lowered to $4 from $7 at RBC Capital

New MarketBeat Followers Over Time

Media Sentiment Over Time

Auxly Cannabis Group stock logo

Auxly Cannabis Group OTCMKTS:CBWTF

$0.06 +0.00 (+1.69%)
As of 06/13/2025 03:42 PM Eastern

Auxly Cannabis Group Inc. operates as a consumer packaged goods company in the cannabis products market in Canada. It focuses on developing, manufacturing, and distributing cannabis products for wellness and recreational consumers. The company offers cannabis products under various forms, including vape catridges, infused pre-rolls, pre-rolled, vape pens, milled and dried flower, concentrates, chocolates, soft chews, oil drops, capsules, and topicals under the KOLAB PROJECT, Dosecann, BACK FORTY, Foray, and Parcel brand names. It sells its products through supply arrangements with provincial control boards and distributors, medical cannabis sales channels, and retailers, as well as to authorized wholesalers. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. The company was incorporated in 1987 and is headquartered in Toronto, Canada.

MaxCyte stock logo

MaxCyte NASDAQ:MXCT

$2.20 -0.07 (-3.08%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$2.21 +0.01 (+0.41%)
As of 06/13/2025 06:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Inotiv stock logo

Inotiv NASDAQ:NOTV

$2.22 -0.13 (-5.53%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$2.22 +0.00 (+0.23%)
As of 06/13/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.

OmniAb stock logo

OmniAb NASDAQ:OABI

$1.78 +0.07 (+4.09%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$1.79 +0.01 (+0.56%)
As of 06/13/2025 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.